PARC report: health outcomes and value of personalized medicine interventions: impact on patient care

被引:6
作者
Mitropoulou, Christina [1 ]
Litinski, Veronika [2 ]
Kabakchiev, Boyko [2 ]
Rogers, Sara [3 ]
Patrinos, George P. [4 ,5 ,6 ]
机构
[1] Golden Helix Fdn, London WC2N 5AP, England
[2] GeneYouIn Inc, Toronto, ON M5B 2L7, Canada
[3] Amer Soc Pharmacovigilance, Houston, TX 77225 USA
[4] Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26504, Greece
[5] United Arab Emirates Univ, Dept Pathol, Coll Med & Hlth Sci, Al Ain, U Arab Emirates
[6] United Arab Emirates Univ, Zayed Ctr Hlth Sci, Al Ain, U Arab Emirates
关键词
economic evaluation; insurance; personalized medicine; pharmacogenetic testing; pharmacogenetics; pharmacogenomics; precision medicine; pricing; reimbursement;
D O I
10.2217/pgs-2019-0194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The incorporation of personalized medicine interventions into routine healthcare constitutes an opportunity to improve patients' quality of life, as it empowers implementation of innovative, individualized clinical interventions that maximize efficacy and/or minimize the risk of adverse drug reactions. In order to ensure equal access to genomic testing for all patients, the costs associated with these interventions must be reimbursed by payers and insurance bodies. As such, it is of utmost importance to thoroughly evaluate these interventions both in terms of their clinical effectiveness and their economic cost. This article discusses the impact of personalized medicine interventions in terms of both health outcomes and value, which directly impacts on their pricing and reimbursement by the various national healthcare systems.
引用
收藏
页码:797 / 807
页数:11
相关论文
共 58 条
[31]  
Mizzi C, 2014, PHARMACOGENOMICS, V15, P1223, DOI [10.2217/PGS.14.102, 10.2217/pgs.14.102]
[32]   User considerations in assessing pharmacogenomic tests and their clinical support tools [J].
Mukerjee, Gouri ;
Huston, Andrea ;
Kabakchiev, Boyko ;
Piquette-Miller, Micheline ;
van Schaik, Ron ;
Dorfman, Ruslan .
NPJ GENOMIC MEDICINE, 2018, 3
[33]   Measuring the Value of Pharmacogenomics Evidence [J].
Patrinos, G. P. ;
Mitropoulou, C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (05) :739-741
[34]   Population pharmacogenomics: impact on public health and drug development [J].
Patrinos, George P. .
PHARMACOGENOMICS, 2018, 19 (01) :3-6
[35]   Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial [J].
Perez, Victor ;
Salavert, Ariana ;
Espadaler, Jordi ;
Tuson, Miquel ;
Saiz-Ruiz, Jeronimo ;
Saez-Navarro, Cristina ;
Bobes, Julio ;
Baca-Garcia, Enrique ;
Vieta, Eduard ;
Olivares, Jose M. ;
Rodriguez-Jimenez, Roberto ;
Villagran, Jose M. ;
Gascon, Josep ;
Canete-Crespillo, Josep ;
Sole, Montse ;
Saiz, Pilar A. ;
Ibanez, Angela ;
de Diego-Adelino, Javier ;
Menchon, Jose M. .
BMC PSYCHIATRY, 2017, 17
[36]   Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study [J].
Perlis, Roy H. ;
Mehta, Rajesh ;
Edwards, Alison M. ;
Tiwari, Arun ;
Imbens, Guido W. .
DEPRESSION AND ANXIETY, 2018, 35 (10) :946-952
[37]   Payer coverage policies for multigene tests [J].
Phillips, Kathryn A. ;
Deverka, Patricia A. ;
Trosman, Julia R. ;
Douglas, Michael P. ;
Chambers, James D. ;
Weldon, Christine B. ;
Dervan, Andrew P. .
NATURE BIOTECHNOLOGY, 2017, 35 (07) :614-617
[38]  
Phillips Kathryn A, 2013, Forum Health Econ Policy, V16, pS23, DOI 10.1515/fhep-2013-0010
[39]   Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions [J].
Pirmohamed, Munir .
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 15, 2014, 15 :349-370
[40]   A dataset quantifying polypharmacy in the United States [J].
Quinn, Katie J. ;
Shah, Nigam H. .
SCIENTIFIC DATA, 2017, 4